F10 and Stroke: The “Rivaroxaban Once Daily Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation” (ROCKET AF) was designed to determine whether rivaroxaban (at a daily dose of 20 mg) is non-inferior to dose-adjusted VKA for the primary end point of stroke (ischaemic and haemorrhagic stroke) or systemic embolism (SE) [14,15].